Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More

This week, AstraZeneca AZN announced its ambition to deliver $80 billion in revenues by 2030, which is significantly higher than $43.8 million generated in 2023. The FDA granted breakthrough therapy designation (“BTD”) to Roche’s https://www.nasdaq.com/articles/pharma-stock-roundup:-azns-2030-sales-target-pfes-new-cost-cut-plan-more